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Use of Screening Tests to Assess Cancer
Risk and to Estimate the Risk of Adult T-
Cell Leukemia/Lymphoma
by Takashi Yanagawa* and Shinkan Tokudomet
We developed methods to assess the cancer risks by screening tests. These methods estimate the size of
the high risk group adjusted for the characteristics of screening tests and estimate the incidence rates of
canceramongthehighriskgroupadjustedforthecharacteristics ofthetests. Amethodwasalsodeveloped
for selecting the cut-offpoint of a screening test. Finally, the methods were applied to estimate the risk
ofthe adult T-cell leukemia/lymphoma.
Introduction
The characteristics of a screening test are usually
expressed by sensitivity and specificity. The sensitivity
(specificity) of a test is the probability that a person
having (not having) the disease is correctly classified.
The prevalence rate ofcanceris frequently estimated
through the use of a screening test. The effects of the
characteristics of the test in estimating disease rates
have been investigated and methods are proposed for
adjustingthe disease rates (1,2)withthe characteristics
ofthe test assumed to be known. Methods ofestimating
the characteristics ofthe test have also been developed
by several authors. Tanenbein (3) considered the use of
a double sampling scheme. Hochberg (4) extended this
to provide a basis for inference from general multidi-
mensional contingency tables. Goldberg and Wittes (5)
applied the capture-recapture model. Hui and Walter
(6) suggested that data are available from any two pop-
ulations with different prevalences and applied the
method of maximum likelihood in estimating simulta-
neously the characteristics of the test and the preva-
lence rates in both populations. Yanagawa et al. (7) and
Yanagawa and Kasagi (8) introduced a study design in
which a person is tested repeatedly at least three dif-
ferenttimes, andtheydeveloped amethodofestimating
prevalence and incidence rates ofdisease together with
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the characteristics of a test. Recently the variance of
an estimator ofthe test characteristics was studied (9).
Inthispaperweconsidercancerssuchasthosecaused
by virus, genetic factors, and the like. The group that
is infected by the virus or that inherits the genetic fac-
tors is called the high riskgroup. We used the situation
where a screening test is employed to judge whether
or not a person belongs to the high risk group. Also we
determine the situation where a person is diagnosed
positive (negative), if and only if the response of the
testexceeds (doesnotexceed)thepredeterminedvalue.
The value is called the cut-off point.
We first proposed a method to determine the cut-off
point ofthe screening test. The point is determined in
such a way to estimate the characteristics of the test
and select the point that minimizes the estimated bias
in estimating the prevalence rate. Next we developed
a method of estimating the size of the high risk group
in a population that adjusts for the characteristics of
the screening test. The method is an extension ofthat
proposed in Yanagawa and Tokudome (10). We next
developed a method of estimating the incidence rates
of cancer among the high risk group. The method ad-
justs forthe characteristics ofthe screeningtest. There
are extensive studies on this topic (11-16), but they do
not discuss the characteristics ofscreeningtests. These
studies assume two binomial variates. An excellent re-
view ofthese methods are given by Gart and Num (16).
On the other hand, the estimation of the risk ratio is
developed by Gart (17), assumingtwo Poisson variates.
WeappliedthePoissonapproximationindevelopingour
estimates. Finally, the methods were applied in esti-
mating the risk ofthe adult T-cell leukemia/lymphoma
(ATLL) in Saga prefecture in Japan.YANAGAWA AND TOKUDOME
Designing a New Screening Test
and Estimating Its Characteristics
We used two tests to design a new screening test and
estimate its characteristics: test 1 was anexpensiveand
sophisticated test that is used in laboratory as a stan-
dard test; test 2 was a simple and quick test, newly
developed for the purpose of mass screening. A person
is diagnosed positive (negative) if and only if the re-
sponse ofthe test exceeds (does not exceed) the value
ofthe predetermined cut-offpoint.
We first considered the problem ofdeciding the cut-
off point of test 2. Usually the cut-off point is decided
bytesting a person byboth tests, summarizingthe data
in a table like that in Table 1, and then selecting the
point among c1, C2,..., Cr+1 (c1 < C2 <. . . < Cr+1) in
the table that provides test 2 with the highest associ-
ationwith test 1. Howcould thisbejustified? Notethat,
although test 1 is more reliable than test 2, it could be
also a fallible test. Ideally, the cut-off point of test 2
should be decided byexaminingits sensitivity and spec-
ificity. The sensitivity andspecificitymutually compete,
and one cannot minimize them simultaneously. To cir-
cumvent this, we proposed to select the cut-off point
among cl, C2, .. ., Cr+l that provided the minimum rel-
ative bias in estimating the prevalence rate.
D _ Jo if person is disease-free
(1 if person has disease
T _ if person test negative by test i
{1 if person test positive by test i, i = 1, 2
Denote the characteristics oftest 1 by:
1-a
1-p,1
= pr{T, = 0 D = 0} = specificity oftest 1
= pr{T, = 1 1 D = 1} = sensitivity oftest 1.
Note that a and p are called false positive and false
negative rates, respectively. We introduce the corre-
sponding quantities a, and Pi for test 2 by:
ai = pr{T2 ci c D = 0}
Pi = pr{T2 < ci D = 1}
since cl < c2 <... < cr+, ai and P,i are restricted by:
aL a2¢. . *. r+l
1
4- 2 -* * * -4- r+
(1)
Table 1. Relationship of test 1 and test 2.
Cut-offpoint Negative Positive Total
Test 1 C. fo,,o fi,o fO
C1 fo,l fil1
Test 2
C, fo, r fi,r fr
Cr + fo, r + I fi, r + I r + 1
Total fo. fi. f.
Nowwhenciis selected asthe cut-offpoint, the prob-
abilityofapersondiagnosedpositivebytest2(apparent
prevalence rate) is
Pi = pr{T2 > Ci}
= aj + P(l- aj -i),
(2)
where P0 stands for the true prevalence rate. There-
fore, the relative bias which will be introduced by test
2 with cut-off point ci is:
Relative bias = {Pi - P0 I/PO
= jai - PO(ai + Ii)IIPo
(3)
Note that the usual method does not necessarily lead
to the cut-offpoint that minimize this bias, even iftest
1 is the perfect test (a = i = 0), since impact of a is
stronger than P in estimating the prevalence rate (2).
Furthermore, note that ifPO is small, the a and P that
minimize Eq. (3) also minimize the mean square errors
when the frequency is employed in estimating PO.
We need estimates ofPO, a, P and ai and Pi, i = 1,
2,..., r + 1 to assess the bias given in Equation (3).
We now describe it by considering the data expressed
inTable 1. Thetotalnumberoftheparameters involved
in it is 3 + 2(r + 1) = 2r + 5, but there is only 2r +
3 degrees offreedominTable 1, unless test 1 isperfect.
Iftest 1 is perfect, all parameters are estimable. But if
test 1 is not perfect, we need to introduce some rea-
sonable restrictions on the parameters to make it es-
timable. Wefindmanycasesthatwemaysupposed ar+1
= Pi = 0, in addition to a1 < 1 and P,+I < 1, which
perhaps reflect the effort of scientists who develop
screening tests.
Put
r+1
f,.= fE i,j, i =0,1 andf . =f. + f.
j=1
When test 1 is perfect (a = , = 0), the estimators of
the parameters are given as follows:
PO = * If..
ai = (fo,i +fo,I +** +fo,r+i)/f . .
Pi = (Vl,o + fi,i + ***+ fli-,i )If * *
i= 1,2,...,r+ 1
When it is supposed that ar+1 = 13 = 0 and a1 < 1,
Pr, < 1, the estimators of the parameters are given
by:
fl,o
fo,o + fl,o'
p = fo,r+ 1
fo,r+ 1 + fl,r+1
1
p° = 1-a _ P [1-a-o(f. /. .)] 0
1 at
-
al = 1 - r )
Pr+l= p (fo, +fi,) - (1 - PO)]
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(1 - Po)(1 - a - 13f..
1 p =
° 1 -aot- P Vn
i--
x (1 - ,8) I, fo,
j=o
= pJ3 foi -
i =2,3,..., r
i-l
- Efi],j
j=o
(i -POM( - oa)(1 -
is an estimate ofthe size ofthe high risk group adjusted
for the characteristics of the test and Za is the upper
(xi) 100(alpha/2)% pointofthestandardnormaldistribution.
' From this we have an approximate 100(1 - alpha)%
confidence limits of the size of the high risk group in
population H1 adjusted for the characteristics of the
screening test as follows:
Estimating Size of the High Risk
Group in a Population by a
Screening Test
Two questions frequently arise: How large is the size
ofthe high risk group ofthe cancer in a population? and
What is the incidence rate ofthe cancer in the high risk
group? In this section we consider the first question;
the secondquestionwillbediscussed inthenextsection.
Let HI be the target population ofsize N and let Q be
a subpopulation that consists ofarandom sample ofsize
n from HI. Suppose that the screening test, with spec-
ificity 1 - a and sensitivity 1 - P, is undertaken to all
subjects in Q to identify the high risk group, aiming to
use the information for estimating the size of the high
risk group in I.
Let X be the size of the high risk group in Q, which
is identified by the screening test. Suppose that X fol-
lows binomial distribution with size n and parameter P.
Let Y be the size ofthe true high risk group in 1H - Q;
suppose that Y follows binomial distribution of size N
- n and parameter P0. Here P0 is the true probability
of a person belonging to the high risk group in II, and
P is the probability of a person diagnosed to be positive
bythe screeningtest. The latter maybe calledapparent
rate; the term true is used to contrast it. Put
T (Xln) -a }+
Note that T represents the size of the true high risk
group in I. We suppose that X and Y are mutually
independent. The constant A that satisfies
X na -A
T X-na
r n(1
- a - ) N n(l - a - )
= 1 - alpha
for given alpha (O<alpha<1) is obtained as
N - n AZa N
+ A}
NT X - a- A (5)
When a = , = 0, the confidence limits agree with that
considered in Yanagawa and Tokudome (10).
Estimating Incidence Rates of
Cancer in the High Risk Group
We considerthe second problem, thatis, the problem
ofestimating the risk ratio p,u = rr IP0, where ff is the
incidence rate of the cancer in HI, and P0 is the true
probability of a person belongs to the high risk group
of the cancer.
Confidence Interval for j,u
Let P again be the probability of a person diagnosed
to be positive by the screening test. Let X and Z be
independent binomial variates based on sample sizes n
and N and parameters P and wr, respectively. We con-
siderthe confidence interval of L,, when nP and NIT are
notlargein asituationwherethePoissonapproximation
to the binomial distribution is appropriate. The approx-
imation has been employed in Gart (17) when no test
characteristics are taken into account.
Using the relationship in Eq. (2), the log likelihood
of x and z is obtained as:
1 = zln ,Lo - N p,Po - n[a + (1 - a - POP
+ zlnPo + xln[a + (1 -a- )PO]
From this we have the maximum likelihood estimate of
,uo as follows:
[zINN
RO = x - na/ n(l- a-
Note that the estimate is the unconditional maximum
likelihood estimate. The conditional arguments by Gart
(17) are not applicable when a > 0 and ,B > 0.
Furthermore, employingthe asymptotic normality of
the maximum likelihood estimate, approximate confi-
dence limits of L,, are obtained as:
, + z [sl - a _ 2 11 +1/2}
Io± z (p -_a)2 LN (p -_ao)2j (6)
[{N n n(l - at- 0p)2 P]
where u is the estimated cancer incidence rate in HI,
and Za is as defined in Eq. (4), and P = x/n. where
- a) (4)
79YANAGAWA AND TOKUDOME
Ifthe value ofPis small, say0.05, then Eq. (6) shows
that a should be extremely small, otherwise the confi-
dencelimitsinflateandestimationoftheriskratiolooses
its validity. Note that Rogan and Gladen (1) indicate
that the screening test with a = 0.05 could be an ex-
tremely good test in practice.
Summary Risk Ratio
Suppose that there are L strata. Let Xi and Zi be
independent binomial variates based on sample sizes
ni and Ni and parameter Pi and fir, respectively
(i= 1,2,... ,L). Let pU =,TJP/Ps where Poi is the true
probability ofaperson inthe stratumibelongingtothe
high risk group ofthe cancer. Putting
Ro = Rol = Po2 = . . . RoL
we formulate the problemforobtaining a summary risk
ratio which summarizes the risk ratios throughout the
strata as the one ofobtaining the estimate of Ro and its
confidence interval.
Now applying the same Poisson approximation as
above, the log likelihood of (xi, zi), i = 1, 2,..., L is
given by:
L
I = z. In,uo - ILo NiPoi
L
- i n[a + (1 -a -P3)Poil
L+ [
+ E zhP.i + xiln[oa+ (1 - a
i=l L - W3)Poi]}
where z. = Zi
From this the maximum likelihood estimate of u¾ is
given by the following procedure:
Step 1: Give an initial estimate of po.
Step 2: Find Pmi (0<Poi<1) by solving the quadratic
equation
aiPoi + bjP,yi + Ci = 0
where
ai = (1 - a - )[RoNj + ni(1 - a - O)]
bi = a[iLoNi + ni(l - a - 1B)]
- (xi + z2)(1 - - (3)
Ci = -az
Step 3: Obtain
z. 'o = L
NiPoi
Step 4: Repeat Step 1-Step 3 until convergence.
An approximate 100(1-alpha)% confidence limit of Ro
is given by:
Ilo ±+ Za[RVZ]
Application to Estimating Risk
of ATLL
The adult T-cell leukemia/lymphoma (ATLL) is the
disease proposed recently (18). The disease is caused
by retrovirus termed humanT-lymphotropic virus type
I (HTLV-I). The disease is endemic in Japan and is
contracted from HTLV-I carriers. The virus may be
transmitted from motherto child and between husband
and wife. Furtherstudies have shownthat HTLV-I can
be transmitted by blood transfusion. The authors were
involved in the project ofestimating the risk ofATLL
in Saga prefecture in Kyushu. The high risk group of
the malignant neoplasm in this study is the one with
HTLV-I carriers. The cases of ATLL were obtained
from the cancer registry and also from related records
in the prefecture. The number of the carriers is esti-
mated by the examination ofthe sera ofblood donors.
It is important to study the bias that might have been
introduced bythe use ofdonor's blood, but we could not
quantify it for various practical reasons. The epidemi-
ologic results of the whole study are published else-
where (19).
Selecting the Cut-off Point
The anti-adult T-cell leukemia/lymphoma-associated
antigen (ATLA) of serum has been examined in the
laboratory by an indirect immunofluorescence (IF) test
using acetone-fixed MT-1 cells on slides as ATLA (20).
When IF dilution ofserum of 1:5 or higher gives a pos-
itiveimmunofluorescence, theserumisjudgedtobe IgG
anti-ATLA-positive. Asimpleand sensitivegelatinpar-
ticle agglutination (PA) procedure has been developed
formass screeningofthe antibodyto HTLV-I inhuman
sera. TheprocedureinthePAtestismuchsimplerthan
that in the IF test or in enzyme-linked immunosorbent
assays (ELISA) because it involves only a one-step re-
action ofantigen and antibody, whereas more steps are
required in the other tests. The titer ofthe antibody in
thePAtestisexpressed asthereciprocalofthegreatest
serum dilution that gives positive reactions.
Several authors (21) suggest selecting 24 as the cut-
off point of the titer in the PA test, namely to judge
the final serum dilution of 1:24 or higher showing ag-
glutination as positive. We examine this cut-off point
based on the data in Table 2, which are given by Ka-
mihira et al. (22). The data have been collected in a
different sampling scheme, but the results in previous
papers (21,23) indicate that we can consider the table
as an example of Table 1. Table 2 lists the results of
19,816 sera tested by both tests. The two estimates of
the parameters from Table 2 that were obtained by
assuming the perfection ofthe IF test and the restric-
tion previously described above, respectively, are
shown to be identical in these data; these estimates are
listedinTable8togetherwiththerelativebiasobtained
from Eq. (3). The table shows that when 24 is selected
asthecut-offpoint, thebiasis0.123; when26isselected,
the bias is 0.007, which is the smallest among the four.
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Table 2. The IF test and the PA test.a
Cut-off point
titer Negative Positive Total
IF test < 2' x 18,809 0 18,809
24 x 37 0 37
PAtest 2r'x 63 16 79
2'x 10 21 31
> 2 x 0 860 860
Total 18,919 897 19,816
'From Kaiiaet al. (22).
Table 3. Estimated characteristics and the relative bias ofthe
PA test for each cut-off point, estimated from the data
in Table 2.'
Cut-offpoint
titer a v Relative bias
24 x 0.00581 0 0.123
25 x 0.00386 0 0.081
2' x 0.00053 0.01784 0.007
> 2' x 0.00000 0.04125 0.041
aa = false positive rate; 13= false negative rate.
Table 4. Estimates ofthe size ofthe HTLV-I carriers and its
95% confidence intervals in Saga.
Age
Paraneter 20-30 30-40 40-50 50-60
Male
Population (N) 51,486 62,229 53,506 52,736
Blood donors (n) 9800 10830 4916 2660
Estimated number ofthe carriers 903 1816 2255 3203
Upper limit 1026 1999 2547 3678
Lower limit 781 1634 1963 2728
Female
Population (N) 59,100 63,706 59,144 59,946
Blood donors (n) 6656 3677 2630 2073
Estimated number ofthe carers 1081 2101 2671 4062
Upper limit 1263 2465 3139 4712
Lower limit 898 1737 2204 3413
Thus we selected 26 as the cut-offpoint ofthe PA test
in our study; this leads to the estimated false positive
and negative rates ofthe PA test as follows:
a = 0.00053, ,3 = 0.01784.
Estimating Number of Carriers
Table 4 shows the data and the estimates ofthe num-
ber of carriers and its confidence intervals. The data
are collected through the PA test with the cut-offpoint
26, and the estimates are obtained by assuming that
a = 0.00053 and p = 0.01784 are known constants. To
see the impact ofthe characteristics ofthe test further,
we obtained the estimates ofthe size ofthe carriers and
its confidence intervals for several values of a and p in
females based on the data in Table 4. These estimates
are summarized in Table 5. The table shows substantial
effect ofthe characteristics; inparticular, the impact on
the younger age group is remarkable.
Table 5. Estimates ofthe carriers in females for selected values
ofa and v based on the data in Table 4.
Confidence Age
a, ,B intervala 20-30 30-40 40-50 50-60
0.005, 0.06 852 1901 2522 3978
UL 1022 2264 2998 4652
LL 682 1539 2205 3304
0.005, 0.10 890 1986 2635 4156
UL 1071 2372 3142 4874
LL 710 1600 2127 3439
0.017, 0.06 95 1098 1786 3251
UL 153 1379 2194 3872
LL 37 817 1377 2630
0.017, 0.10 99 1148 1867 3398
UL 161 1447 2302 4060
LL 37 848 1431 2736
aUL = upper level of the 95% confidence interval; LL = lower
level ofthe 95% confidence interval.
Table 6. Incidence rates ofATLL among the HTLV-I carriers in
Saga (x 10-5).
Age
Parameter 30-40 40-50 50-60 Summary
Male
Population (N) 62,229 53,506 52,736
Deaths: 3 years 0 8 11
Incidence rate 0 118.2 114.5 116.1a
(63.9-168.3)b
Female
Population (N) 63,706 59,144 59,946
Deaths: 3 years 3 5 7
Incidence rate 47.6 62.4 57.4 56.6e
(27.9-85.2)b
'Summary of age 40-60 years.
b95% Confidence interval.
'Summary ofage 30-60 years.
Estimating Incidences ofATLL
among Carriers
Table 6 lists the numberofcases ofATLL for3years
and also shows the population in Saga prefecture be-
tween the ages of 30 to 60. No cases of ATLL are re-
ported in ages 20 to 40 in males and age 20 to 30 in
females. Table 6 also liststhe estimates oftheincidence
rates of ATLL among the HTLV-I carriers in males
and females and its summary rates. The estimates are
obtained by the method developed in the text. It was
supposed that a = 0.00053, p = 0.01784 are known
constants. To study the impact ofthe characteristics of
the test, estimates were obtained for several values of
a and , in females based on the data in Tables 4 and 6.
The estimates are summarized in Table 7. The table
shows substantial impact for large values of a. Since
there is no incidence ofATLL for the group ages 20 to
30 onwhichtheimpactisthegreatest, aswasdiscussed
previously, the table shows that the impact ofthe char-
acteristics of the screening test on the summary risk
ratio is not so strong as the estimation ofthe size ofthe
carriers. Note that ifthe values ofa exceed 0.032, the
81YANAGAWA AND TOKUDOME
Table 7. Estimated incidence rates ofATLL among the carriers
in females for selected values of a and e based on the data in
Table 6 ( x 10-5).
Age
a, 13 30-40 40-50 50-60 Summary
0.005, 0.06 52.6 66.1 58.7 59.5
(29.4-89.6)a
0.005, 0.10 50.3 63.3 56.1 57.0
(28.1-85.8)a
0.017, 0.06 91.1 93.3 71.8 81.5
(40.3-122.9)a
0.017, 0.10 87.1 89.3 68.7 78.0
(38.5-117.5)a
0.032, 0.10 150.2 190.1 96.4 141.3
(69.8-212.8)a
a95% Confidence interval.
summary risk ratio in age group 30 to 60 is not obtain-
able because ofthe strong impact, in particular, on age
30 to 40.
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